REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL) ALLO-316: ccRCC ALLO-329: autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A […]